Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia

Hanlim Pharm

Status and phase: Completed; Phase 3

Conditions: Primary Hypercholesterolemia

Treatments: Drug: Rosuvastatin 20mg → HL140 20/10; Drug: Rosuvastatin 10mg → HL140 10/10; Drug: HL140 20/10; Drug: HL140 10/10; Drug: HL140 5/10; Drug: Rosuvastatin 5mg → HL140 5/10

Study type: Interventional

Funder types: Industry

Identifiers

NCT03571087

HL_HL140_301

Details and patient eligibility

About

The purpose of this study is to evaluate efficacy and safety of HL140 in patients with primary hypercholesterolemia.

Full description

The purpose of this study is to demonstrate that the efficacy of combination drug of rosuvastatin/ezetimibe is superior to single rosuvastatin drug and to confirm the safety of combination drug of rosuvastatin/ezetimibe

Enrollment: 374 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged over 19 years
• Signed informed consent form
• At visit 1 and visit 2, LDL-Cholesterol ≤ 250mg/dL and Triglyceride ≤ 400mg/dL

Exclusion criteria

• At visit 1, BMI ≥ 30kg/㎡

• Has a history of myopathy or rhabdomyolysis cased by statin treatment, hereditary myopathy or family history and hypersensitivity to statin(HMG-CoA reductase inhibitor) and component of ezetimibe

• Has a Severe renal disorder(Ccr <30mL/min) or nephrotic syndrome

• Creatine Kinase > 5 x upper limit of normal

• ALT or AST > 3 x upper limit of normal

• Has a activity/chronic hepatic disease or HIV-positive

• Has a endocrine or metabolic diseases known to affect the serum phospholipid or protein

  • Uncontrolled diabetes mellitus(HbA1c ≥9%)
  • Hypothyroidism (TSH > 1.5 x upper limit of normal rate at the screening )

• Uncontrolled hypertension (SBP ≥180mmHg or DBP ≥110mmHg)

• Has a acute arteriopathy(history of unstable angina, cardiac infarction, transient ischemic stroke, cerebrovascular disease, coronary artery bypass, coronary intervention within 12 weeks prior to screening)

• Severe heart failure (NYHA Class III or IV)

• Has a drug absorption disorder by gastrointestinal surgery or gastrointestinal disorder

• History of malignant tumor including myelogenous and lymphoma within 5 years (Participation is possible, if the tumor has not recurred for more than 5 years)

• Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption

• Female subjects of childbearing potential who disagree with the contraceptive methods(surgical sterilization, intrauterine device or condoms)

• Pregnant or breast-feeding

• Patients who have a drug or alcohol abuse or are being treated for psychological disorder

• Patients who were treated with other investigational drug within 12 weeks prior to screening

• Other patients who are inappropriate to participate in the study considered by the investigator or other study staffs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

374 participants in 6 patient groups

HL140 5/10

Experimental group

Description:

Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)

Treatment:

Drug: HL140 5/10

HL140 10/10

Experimental group

Description:

Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)

Treatment:

Drug: HL140 10/10

HL140 20/10

Experimental group

Description:

Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)

Treatment:

Drug: HL140 20/10

Rosuvastatin 5mg → HL140 5/10

Experimental group

Description:

1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg 2. Extension period(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)

Treatment:

Drug: Rosuvastatin 5mg → HL140 5/10

Rosuvastatin 10mg → HL140 10/10

Experimental group

Description:

1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg 2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)

Treatment:

Drug: Rosuvastatin 10mg → HL140 10/10

Rosuvastatin 20mg → HL140 20/10

Experimental group

Description:

1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 20mg 2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)

Treatment:

Drug: Rosuvastatin 20mg → HL140 20/10